Our Scientific Advisors

MSc, PhD

University of Mississippi Medical Center

Targeted antitumor therapies have been my focus and passion for many years. To this work I bring broad training in biophysics, molecular and cell biology, and bioengineering. As a post-doctoral fellow at Duke University, I focused on the study of recombinant DNA for the design and synthesis of genetically engineered biopolymers, their biophysical characterization, and their application in biotechnology and drug delivery. Upon joining the University of Mississippi Medical Center, I began to develop ELP-based fusion proteins able to target specific cellular compartments, while pioneering the use of cell penetrating elastin-like polypeptides for the delivery of therapeutic peptides to modulate the activity of aberrant molecular pathways in cancer.

My prior work of relevance to the proposed project has included the development of externally triggered, bioengineered delivery systems for specific chemotherapeutic agents to further safe, effective treatments of brain, breast, pancreatic, and prostate tumors.

Expertise: Targeted Antitumor Therapies

B. Sc. Ph.D.

A leader in drug development strategy and regulatory science with a track record of achievement in a range of therapy areas. A business leader with experience of building external partnerships and internal change management. A strong leader and motivator who has held senior positions in a range of service and pharma companies. A specialist in discovery and regulatory development of neglected and orphan diseases. 

Drug development consultancy start-up serving SME and Biotech companies in range of therapeutic indications including oncology, infection, inflammatory and stroke. Responsible for drug development projects supporting key areas in translational sciences including CMC, nonclinical, clinical, commercial and regulatory strategies for biological and small molecules. Project Leader in US biologic development in MDS, with expansion to EU and Japan. 

Project leader for EMA MAA registration of Pyramax antimalarial for tablet and granules under Article 58 (Approved October 2015). Ongoing leadership of peri and post approval programme of Pyramax with registrations, clinical trials and commercialisation (liaison with MOH, partner support plus marketing support). Continuing work on capacity building in Africa and support to WHO programmes in harmonized regulatory submissions (Africa and Asia) and in centralised pharmacovigilance systems (eg. CNPV Kinshasa). 

Expertise: Regulatory & Development

BSc (Hons), PhD

A strong scientific and technical background, and the ability to think and operate strategically. Has worked in both large Pharma and Biotech sectors, and demonstrated excellence in project initiation and delivery, and in strategic leadership. Both a team player and a team leader in contributing to the success of global, cross-disciplinary Discovery and Development teams. Experience in Clinical Development teams, and an excellent awareness of success factors required for commercial success of new therapeutic entities. As a consultant, has demonstrated ability to provide crisp and focussed, yet detailed evaluations of new mechanisms and therapeutic agents, with a particular emphasis on risk analysis and mitigation plans. Has experience of running start-up companies, including strategic planning, staff management and delivery of business plans to schedule. 

• Creative and innovative immunologist with a passion for drug discovery
• Demonstrated exceptional leadership of scientific projects and cross functional portfolio teams to deliver results within AstraZeneca, CAT and MedImmune
• Broad knowledge and experience of drug discovery and development
• Experience of running start up biotechnology companies, and devising and delivering business plans to tight budgets and timelines
• Considerable experience working with clients to deliver sound due diligence output of novel mechanisms and new therapeutic entities
• Excellent track record of recognising, developing, selling and delivering ideas for novel therapeutic entities to create value
• Strong influencing skills with peer scientists and particularly with non-specialists.

Excellent communication skills – including the ability to explain complex and highly technical scientific information to non-scientists

Expertise: Drug Discovery